The intervention showed no clear difference in SAEs ‐ formoterol versus salbutamol ( (moderate certainty).
The intervention showed no clear difference in mortality (all‐cause) ‐ formoterol versus salbutamol ( (moderate certainty).
The review found no eligible studies for this question.
Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ adults and adolescents compared with regular salbutamol (moderate certainty).
Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ children compared with regular salbutamol (moderate certainty).
Regular salmeterol showed no clear difference in asthma‐related mortality ‐ adults and adolescents compared with regular salbutamol (moderate certainty).
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ adults and… compared with regular salbutamol (low certainty).
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ children compared with regular salbutamol (low certainty).
Regular salmeterol showed no clear difference in all‐cause mortality ‐ adults and adolescents compared with regular salbutamol (moderate certainty).
Regular salmeterol showed no clear difference in all‐cause mortality ‐ children compared with regular salbutamol (low certainty).